Diabetes 2030 Forecasts, 2015

NORTH DAKOTA Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	635,100	630,100	620,800	606,600
Prediabetes	170,500	174,700	177,300	173,400
Diagnosed diabetes	41,100	48,300	53,500	56,500
Undiagnosed diabetes	17,900	20,000	21,000	21,000
Total with diabetes (diagnosed and undiagnosed)	59,000	68,300	74,500	77,500
Complications:				
Visual impairment	6,700	7,700	8,300	8,500
Renal failure	98	110	120	120
Leg amputations	85	92	94	91
Annual deaths attributable to diabetes	440	500	520	520
Total annual cost (2015 dollars)	$623 M	$714 M	$776 M	$806 M
Annual medical costs	$466 M	$530 M	$574 M	$594 M
Annual nonmedical costs	$157 M	$184 M	$202 M	$212 M

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	107,900	125,000	142,200	152,400
Prediabetes	55,000	63,800	72,500	77,700
Diagnosed diabetes	20,400	23,600	26,900	28,800
Undiagnosed diabetes	7,500	8,800	9,900	10,700
Total with diabetes (diagnosed and undiagnosed)	27,900	32,400	36,800	39,500
Complications:				
Visual impairment	3,800	4,300	4,800	5,000
Renal failure	63	70	77	80
Leg amputations	47	51	53	53
Annual deaths attributable to diabetes	310	330	340	330
Total annual cost (2015 dollars)	$357 M	$414 M	$470 M	$504 M
Annual medical costs	$335 M	$388 M	$441 M	$473 M
Annual nonmedical costs	$22 M	$26 M	$29 M	$31 M

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.